Stay updated on Pembrolizumab Combo in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check19 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1.0%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check76 days agoChange DetectedThe page has been updated to include new drug information and identifiers related to a clinical trial for non-small cell lung cancer, while significant details about the trial's design and inclusion/exclusion criteria have been removed.SummaryDifference22%
Stay in the know with updates to Pembrolizumab Combo in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.